Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 25, 2016

View Archived Issues

Sanuwave says it's back in the race for diabetic foot ulcer treatment

Researchers affirm arterial calcification predictive of CAD

Smallest genomed-bacterium addresses very big questions

Neurostim to hit $6.2B by 2020 Stimwave gets FDA nod for its peripheral nerve stimulator

Generic opioid guidance not a knockout; other pain solutions needed

Product briefs

Other news to note

Daily M&A

Financings

Diagnostics Extra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...